2021 FDA Safety Warning Impact on JAK Inhibitor Prescribing Among Rheumatologists: A Nationwide Analysis 2018-2023 (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2771; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "These included JAK inhibitors (tofacitinib, baricitinib, upadacitinib); TNFi (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab); non-TNFi biologics (abatacept, tocilizumab, rituximab, sarilumab); IL-17 inhibitors (secukinumab, ixekizumab, bimekizumab); IL-12/23 inhibitor (ustekinumab); and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). The 2021 FDA boxed warning was associated with a significant decrease of JAKi share growth, with tofacitinib declining the most, while newer JAK inhibitors continued to grow. The warning effect was uniform across U.S. regions and prescriber gender, indicating broadly consistent uptake of the safety signal. These findings extend prior work to the U.S. Medicare population, demonstrating rapid, drug-specific incorporation of safety signals into clinical practice."
Clinical • Cardiovascular • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Thrombosis • IL12A • IL17A • IL23A
|
|
Celestine He1; Zhonghan Li2; Chrisanna Dobrowolski3
|